Neutrophil elastase and its therapeutic effect on leukemia cells

Jiang,Kai‑Ling; Ma,Peng‑Peng; Yang,Xiao‑Qun; Zhong,Liang; Wang,Hui; Zhu,Xin‑Yu; Liu,Bei‑Zhong

doi:10.3892/mmr.2015.3946

Neutrophil elastase and its therapeutic effect on leukemia cells

Authors:
- Kai‑Ling Jiang
- Peng‑Peng Ma
- Xiao‑Qun Yang
- Liang Zhong
- Hui Wang
- Xin‑Yu Zhu
- Bei‑Zhong Liu
View Affiliations

Affiliations: Central Laboratory of Yong‑Chuan Hospital, Chongqing Medical University, Chongqing 402160, P.R. China, Key Laboratory of Laboratory Medical Diagnostics, Ministry of Education, Department of Laboratory Medicine, Chongqing Medical University, Chongqing 400016, P.R. China
Published online on: June 17, 2015 https://doi.org/10.3892/mmr.2015.3946
Pages: 4165-4172
Copyright: © Jiang et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Neutrophil elastase (NE) is an early myeloid-specific serine protease, which is predominantly produced by promyelocytes. A previous study demonstrated that NE has an important role in the development of acute promyelocytic leukemia (APL). The process of APL was shown to be accelerated in animals that expressed abundant NE, whereas NE‑deficient mice were protected from APL development; thus suggesting an important role for NE in the development of APL. The present study aimed to investigate the effects and possible mechanisms of NE. Up- and downregulation of NE in various leukemia cell lines was conducted in order to explore its significance in the occurrence and procession of leukemia, with the aim of identifying novel targeted therapeutic drugs for the treatment of leukemia. NE was overexpressed in cells following infection with an adenovirus, and Cell Counting kit‑8 and flow cytometry results demonstrated that cell proliferation was promoted, and cell apoptosis was inhibited, as compared with the untreated cells. NE was downregulated in the cells by both RNA interference and treatment with GW311616A, a specific inhibitor of NE, following which cell growth was shown to be inhibited and apoptosis was induced. These results suggested that NE may promote the development of APL, therefore, NE may be a therapeutic target and its inhibitor GW311616A may be a potential therapeutic drug for leukemia. Furthermore, the apoptosis‑associated protein B‑cell lymphoma 2 (Bcl‑2)‑associated X protein was significantly increased, whereas Bcl‑2 was markedly decreased in the cells with downregulated NE. Further experiments revealed that the probable apoptosis‑associated signaling pathway was the phosphoinositide 3‑kinase/AKT pathway. The present study is the first, to the best of our knowledge, to demonstrate that GW311616A, a specific NE inhibitor, may act as a potential targeted drug for leukemia, which may have a profound impact on the future of leukemia-targeted therapy.

View Figures

View References

1	Papayannopoulos V, Metzler KD, Hakkim A and Zychlinsky A: Neutrophil elastase and myeloperoxidase regulate the formation of neutrophil extracellular traps. J Cell Biol. 191:677–691. 2010. View Article : Google Scholar : PubMed/NCBI
2	Korkmaz B, Moreau T and Gauthier F: Neutrophil elastase, proteinase 3 and cathepsin G: Physicochemical properties, activity and physiopathological functions. Biochimie. 90:227–242. 2008. View Article : Google Scholar
3	Mansuy-Aubert V, Zhou QL, Xie X, Gong Z, Huang JY, Khan AR, Aubert G, Candelaria K, Thomas S, Shin DJ, et al: Imbalance between neutrophil elastase and its inhibitor α1-antitrypsin in obesity alters insulin sensitivity, inflammation, and energy expenditure. Cell Metab. 17:534–548. 2013. View Article : Google Scholar : PubMed/NCBI
4	Kawabata K, Hagio T and Matsuoka S: The role of neutrophil elastase in acute lung injury. Eur J Pharmacol. 451:1–10. 2002. View Article : Google Scholar : PubMed/NCBI
5	Tamakuma S, Ogawa M, Aikawa N, Kubota T, Hirasawa H, Ishizaka A, Taenaka N, Hamada C, Matsuoka S and Abiru T: Relationship between neutrophil elastase and acute lung injury in humans. Pulm Pharmacol Ther. 17:271–279. 2004. View Article : Google Scholar : PubMed/NCBI
6	Sato T, Takahashi S, Mizumoto T, Harao M, Akizuki M, Takasugi M, Fukutomi T and Yamashita J: Neutrophil elastase and cancer. Surg Oncol. 15:217–222. 2006. View Article : Google Scholar
7	Ho AS, Chen CH, Cheng CC, Wang CC, Lin HC, Luo TY, Lien GS and Chang J: Neutrophil elastase as a diagnostic marker and therapeutic target in colorectal cancers. Oncotarget. 30:473–480. 2014.
8	Lane AA and Ley TJ: Neutrophil elastase cleaves PML-RARalpha and is important for the development of acute promyelocytic leukemia in mice. Cell. 115:305–318. 2003. View Article : Google Scholar : PubMed/NCBI
9	Lane AA and Ley TJ: Neutrophil elastase is important for PML-retinoic acid receptor alpha activities in early myeloid cells. Mol Cell Biol. 25:23–33. 2005. View Article : Google Scholar :
10	Lee SK, Son BS, Hwang JJ, et al: The use of neutrophil elastase inhibitor in the treatment of acute lung injury after pneumonectomy. J Cardiothorac Surg. 8(69)2013. View Article : Google Scholar
11	Lee WL and Downey GP: Leukocyte elastase: Physiological functions and role in acute lung injury. Am J Respir Crit Care Med. 164:896–904. 2001. View Article : Google Scholar : PubMed/NCBI
12	Hoshi K, Kurosawa S and Kato M: Sivelestat, a neutrophil elastase inhibitor, reduces mortality rate of critically ill patients. Tohoku J Exp Med. 207:143–148. 2005. View Article : Google Scholar : PubMed/NCBI
13	Macdonald SJ, Dowle MD, Harrison LA, Shah P, Johnson MR, Inglis GG, Clarke GD, Smith RA, Humphreys D, Molloy CR, et al: The discovery of a potent, intracellular, orally bioavailable, long duration inhibitor of human neutrophil elastase - GW311616A a development candidate. Bioorg Med Chem Lett. 11:895–898. 2001. View Article : Google Scholar : PubMed/NCBI
14	Ohbayashi H: Neutrophil elastase inhibitors as treatment for COPD. Expert Opin Investig Drugs. 11:965–980. 2002. View Article : Google Scholar : PubMed/NCBI
15	Miyoshi S, Hamada H, Ito R, Katayama H, Irifune K, Suwaki T, Nakanishi N, Kanematsu T, Dote K, Aibiki M, et al: Usefulness of a selective neutrophil elastase inhibitor, sivelestat, in acute lung injury patients with sepsis. Drug Des Devel Ther. 7:305–316. 2013. View Article : Google Scholar : PubMed/NCBI
16	Luo J, Deng ZL, Luo X, et al: A protocol for rapid generation of recombinant adenoviruses using the AdEasy system. Nature Protocols. 2:1236–1247. 2007. View Article : Google Scholar : PubMed/NCBI
17	Horwitz M, Benson KF, Person RE, Aprikyan AG and Dale DC: Mutations in ELA2, encoding neutrophil elastase, define a 21-day biological clock in cyclic haematopoiesis. Nat Genet. 23:433–436. 1999. View Article : Google Scholar : PubMed/NCBI
18	Akizuki M, Fukutomi T, Takasugi M, Takahasi S, Sato T, Harao M, Mizumoto T and Yamashita J: Prognostic significance of immunoreactive neutrophil elastase in human breast cancer: Long-term follow-up results in 313 patients. Neoplasia. 9:260–264. 2007. View Article : Google Scholar : PubMed/NCBI
19	Wislez M, Antoine M, Rabbe N, Gounant V, Poulot V, Lavolé A, Fleury-Feith J and Cadranel J: Neutrophils promote aerogenous spread of lung adenocarcinoma with bronchioloalveolar carcinoma features. Clin Cancer Res. 13:3518–3527. 2007. View Article : Google Scholar : PubMed/NCBI
20	Moroy G, Alix AJ, Sapi J, Hornebeck W and Bourguet E: Neutrophil elastase as a target in lung cancer. Anticancer Agents Med Chem. 12:565–579. 2012. View Article : Google Scholar : PubMed/NCBI
21	Zhang X, Zhong L, Liu BZ, Gao YJ, Gao YM and Hu XX: Effect of GINS2 on proliferation and apoptosis in leukemic cell line. Int J Med Sci. 10:1795–1804. 2013. View Article : Google Scholar : PubMed/NCBI
22	Buggins AG and Pepper CJ: The role of Bcl-2 family proteins in chronic lymphocytic leukaemia. Leuk Res. 34:837–842. 2010. View Article : Google Scholar : PubMed/NCBI
23	Li Y, Yin S, Nie D, Xie S, Ma LM, Wang X, Wu Y and Xiao J: MK886 inhibits the proliferation of HL-60 leukemia cells by suppressing the expression of mPGES-1 and reducing prostaglandin E2 synthesis. Int J Hematol. 94:472–478. 2011. View Article : Google Scholar : PubMed/NCBI
24	Korsmeyer SJ: BCL-2 gene family and the regulation of programmed cell death. Cancer Res. 59(7 Suppl): 1693s–1700s. 1999.PubMed/NCBI
25	Ola MS, Nawaz M and Ahsan H: Role of Bcl-2 family proteins and caspases in the regulation of apoptosis. Mol Cell Biochem. 351:41–58. 2011. View Article : Google Scholar : PubMed/NCBI
26	Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ and Green DR: The BCL-2 family reunion. Mol Cell. 37:299–310. 2010. View Article : Google Scholar : PubMed/NCBI
27	Willis S, Day CL, Hinds MG and Huang DC: The Bcl-2-regulated apoptotic pathway. J Cell Sci. 116:4053–4056. 2003. View Article : Google Scholar : PubMed/NCBI
28	Juin P, Geneste O, Raimbaud E and Hickman JA: Shooting at survivors: Bcl-2 family members as drug targets for cancer. Biochim Biophys Acta. 1644:251–260. 2004. View Article : Google Scholar : PubMed/NCBI
29	Osaki M, Oshimura M and Ito H: PI3K-Akt pathway: Its functions and alterations in human cancer. Apoptosis. 9:667–676. 2004. View Article : Google Scholar : PubMed/NCBI
30	Chang F, Lee JT, Navolanic PM, Steelman LS, Shelton JG, Blalock WL, Franklin RA and McCrubey JA: Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: A target for cancer chemotherapy. Leukemia. 17:590–603. 2003. View Article : Google Scholar : PubMed/NCBI
31	Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C and González-Barón M: PI3K/Akt signalling pathway and cancer. Cancer Treat Rev. 30:193–204. 2004. View Article : Google Scholar : PubMed/NCBI
32	Ma PP, Zhu D, Liu BZ, Zhong L, Zhu XY, Wang H, Zhang X, Gao YM and Hu XX: Neutrophil elastase inhibitor on proliferation and apoptosis of U937 cells. Zhonghua Xue Ye Xue Za Zhi. 34:507–511. 2013.In Chinese. PubMed/NCBI